Phoenix Molecular Designs

Phoenix is developing inhibitors of the RSK kinase as treatment for Triple-Negative Breast Cancer, an aggressive and difficult to treat form of cancer.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Richmond, BC, Canada
  • Currency CAD
  • Founded June 2012
  • Employees 10
  • Incorporation Type C-corp
  • Website phoenixmd.ca

Company Summary

PhoenixMD has designed a new class of cancer therapeutics targeting kinases known as “RSK”. RSK remains active in cancer cells that survive traditional chemotherapies, thus are central to cancer recurrence. RSK is linked to numerous cancer types including breast, prostate, colon, lung and brain cancers. Our initial focus is on triple negative breast cancer, the deadliest form of breast cancer with an annual incidence of 400,000 patients

Team

  • John Van Drie
    Chief Technology Officer

    John is trained as a computational chemist with specific expertise in drug development. He previously led drug discovery operations at Novartis, Pharmacia and Vertex. Currently he is located in Boston, Mass at the hub of biotechnology in the United States.

  • Hooshmand Sheshbaradaran
    Chief Business Officer

    Hooshmand has decades of experience in pharmaceutical development as a business strategist and leader in partnership development. He is currently a multinational consultant with Novateur. His experience is vast ranging from small biotech start ups to large pharmaceutical companies such as Pfizer and Roche. In particular, he has been instrumental in the development of a number of oncology drugs.

Advisors

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free